List view / Grid view
This in-depth focus features articles on using combinations of immuno-oncology drugs to target solid tumours and haematological cancers and how neoantigens of cancer cells could be used as the basis of novel immuno-oncology vaccines.
Exploring how therapies with multi-faceted approaches could improve options for treatment-refractory cancers, like pancreatic and triple-negative breast cancer.
Researchers have created a new kind of immunotherapy using the interleukin-27 (IL-27) cytokine to effectively combat tumours in vitro and in vivo.
A new CAR T-cell therapy has been created by researchers which targets three proteins on leukaemia cells and has shown success in pre-clinical trials.
Researchers have developed a new CAR T-cell therapy that targets an antigen called glycipan-1 (GPC1), showing efficacy at fighting solid tumours in mice.
A new study has shown that the role of T cell-suppressing dendritic cells can be reversed in mice, indicating that immunotherapies could be improved with this method.
By removing two kinds of macrophages in mice, researchers showed that ovarian tumours in mice were reduced in size and stopped spreading.
Researchers have shown that natural killer (NK) cells work best as an immunotherapy when in an early stage of development, so could be manufactured from pluripotent stem cells.
This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve drug discovery and an analysis of whether antibodies can provide an effective coronavirus treatment. Other article topics in this issue include immuno-oncology and artificial intelligence.
Identifying next generation targets for cancer immunotherapy.
Researchers have found that there is less calmodulin binding to ion channels in the T cells from cancer patients, presenting a new immunotherapeutic target.
Combining the chlorotoxin peptide with conventional CAR structures, researchers have created a new CAR T cell therapy that has successfully combatted glioblastomas in mice.
Researchers have discovered that a small molecule can help some T cells combat tumours during PD-1 blockade immunotherapy in mice.
A study has shown that in mice, the GKT137831 drug makes tumours more sensitive to immunotherapy, so could be used to improve cancer treatments.
Drug Target Review spoke with CUE Biopharma’s President and CSO to find out how and why they created the ImmunoSTAT platform and the ways it may benefit drug design in the future.
